Please login to the form below

Not currently logged in
Email:
Password:

Moderna Therapeutics appoints chief business officer

Saqib Islam brings experience from Alexion Pharmaceuticals

Moderna Therapeutics Saqib IslamCambridge, Massachusetts-based Moderna Therapeutics has appointed Saqib Islam as its new chief business officer from 9 May.

Islam will take on responsibility for Moderna's global strategic planning, corporate and business development functions as the biotech firm looks to advance its pipeline.

Stéphane Bancel, chief executive officer at Moderna, said: “We are thrilled to welcome Saqib to our team; his expertise, intellect and drive for excellence are a perfect fit for Moderna.”

Islam joins from Alexion Pharmaceuticals, where he served as executive vice president and chief strategy officer from 2013. In this role, he held primary responsibility for executing the firm's corporate growth strategies and oversaw the management of its global operations.

He brings over 20 years of international business management expertise to Moderna, having held increasingly senior roles at The Boston Consulting Group, Merrill Lynch, Morgan Stanley and Credit Suisse Securities.

Islam said: “Already a clinical stage company, Moderna has extraordinary opportunities ahead of it, with its breakthrough science, accelerated discovery engine and unique business model.

“I look forward to working closely with Stéphane and the leadership team as we evaluate these opportunities and evolve Morderna's internal development and external partnering strategies to support the creation and commercialisation of a new generation of transformative medicines for patients.”

12th April 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics